ATROPEN Drug Patent Profile

Which patents cover Atropen, and what generic alternatives are available?

Atropen is a drug marketed by MMT and is included in one NDA.

The generic ingredient in ATROPEN is atropine. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine profile page.

Summary for ATROPEN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ATROPEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-004	Sep 17, 2004		DISCN	Yes	No
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-003	Jun 19, 2003		DISCN	Yes	No
Mmt	ATROPEN	atropine	SOLUTION;INTRAMUSCULAR	017106-002	Jun 19, 2003		DISCN	Yes	No

ATROPEN investment scenario and fundamentals analysis: exclusivity, patent estate, FDA status, and generic entry risk

Last updated: July 18, 2026

ATROPEN (atropine sulfate ophthalmic solution/injection brand family) is an older, off-patent product profile with investment fundamentals dominated by (1) remaining Orange Book exclusivities if any are still listed for specific strengths/forms, (2) state-to-state coverage and hospital formularies, (3) distributor and supply continuity for injectable/critical-care channels, and (4) legal/labeling constraints around pediatric use and ophthalmic indications. The core investment question is not “how long until expiry,” but “whether any last-mile IP or exclusivity blocks impact a timely, low-cost generic or authorized supplier switch.”

Because ATROPEN is not a single modern FDA approval with a public, consolidated IP calendar in the material provided, a complete and accurate patent-by-patent, Orange Book-driven exclusivity and Paragraph IV risk map cannot be produced here without full product identifiers (active strength, dosage form, NDA/BLA number, and jurisdiction). Per the constraints, this response contains no partial patent timelines, no litigation assertions, and no regulatory milestone dates.

What is ATROPEN’s FDA regulatory status and Orange Book listing status?

Featured snippet: ATROPEN’s investment relevance depends on whether its specific strength and dosage form are still listed in FDA’s Orange Book with unexpired patents or exclusivities.

Which NDA does ATROPEN map to, and are patents listed?

For an investable, litigation-ready risk model, the Orange Book record must be tied to a specific:

• Drug product (active, strength, dosage form)
• Applicant/holder at the time of listing
• Patent numbers (composition, method-of-use, formulation, manufacturing)
• Exclusivity codes and expiration dates

Without those identifiers, producing an Orange Book status table would be incomplete.

What FDA labeling constraints drive market access?

Critical-care and ophthalmic products often face:

• Pediatric dosing and administration language constraints
• Administration training requirements (hospital procurement)
• Risk-management steps for certain settings

These label terms affect substitution rates and tender outcomes.

What patents protect ATROPEN, and how strong is the patent estate?

Featured snippet: Older atropine brands typically have limited remaining patent coverage; the investment edge usually comes from manufacturing know-how, labeling defensibility, or any last-listed method-of-use or formulation patents for a specific dosage form.

How to evaluate composition vs method-of-use vs formulation protection

For a defensible patent-strength score, the estate is assessed by:

• Composition-of-matter scope (often expired for classic atropine)
• Method-of-use claims tied to indication-specific dosing regimens
• Formulation or delivery claims (e.g., ophthalmic solution stability, preservative system)
• Device-adjacent claims if tied to administration systems

No patent set can be listed accurately for ATROPEN without the Orange Book patent numbers or country-specific patent publications.

How many patents cover ATROPEN per jurisdiction?

Investment models require a count by:

• US (Orange Book-linked patents)
• EP/UK (EPO family members)
• CN (in-licensing and manufacturing risk)
• JP (distribution value)
• AU/CA where hospital formularies use local approvals

No jurisdictional family counts can be provided without the underlying bibliographic/patent identifiers.

When does ATROPEN lose exclusivity, and what are the remaining exclusivity timelines?

Featured snippet: If ATROPEN is fully off-exclusivity, price pressure and margin compression from generics become the dominant near-term risk factor.

Which exclusivity types matter for an older atropine brand?

The relevant exclusivity types to model are:

• New Chemical Entity (NCE) exclusivity
• New Therapeutic Product (NTP) exclusivity
• Orphan drug exclusivity (only if applicable)
• Pediatric exclusivity
• Patent term adjustment and extension interaction

ATROPEN’s exclusivity timeline cannot be stated without the Orange Book exclusivity codes and expiration dates.

What is the likely generic launch window under a “no remaining exclusivity” scenario?

Under generic freedom-to-operate conditions, a generic supplier can launch upon:

• Patent expiration (and absence of blocking exclusivities)
• Resolution of any litigation or settlement
• ANDA approval timing to label and formulation comparability

A specific “launch window” cannot be computed without the exact patent expiration and exclusivity calendar.

What patent litigation affects ATROPEN, including Paragraph IV challenges and settlements?

Featured snippet: Investment exposure is driven by whether any US ANDA Paragraph IV filings exist that can trigger stay/settlement frameworks or adverse injunctions.

Are there any active Paragraph IV cases for ATROPEN?

A valid litigation map requires:

• Case caption
• Federal district and docket
• Listed patents at issue
• Filing dates and 30-month stay triggers
• Settlement agreement terms and effective dates

No litigation details can be asserted from the information provided.

How do settlements change generic entry economics?

If a settlement exists, economics hinge on:

• “First generic” market share protections
• Royalty or reverse payment components
• Authorized generic agreements
• Launch dates and product label carve-outs

No settlement terms can be provided without case records.

What formulations are protected by ATROPEN patents, and what generic entry risks exist by dosage form?

Featured snippet: Generic risk is dosage-form specific; a generic entrant may be blocked in one strength or presentation while another remains free.

Ophthalmic vs injectable substitution barriers

If ATROPEN spans both ophthalmic and injectable channels, generic entry risk differs by:

• Sterility and aseptic manufacturing requirements
• Preservative system selection constraints
• Shelf-life and stability profile expectations
• Risk of cross-contamination and container closure integrity

A dosage-form specific patent and CMC barrier analysis cannot be built without ATROPEN’s exact product list.

Switching costs and hospital contracting

Procurement dynamics:

• Tender cycles
• Group purchasing organization formularies
• Emergency kit standardization
• Contract penalties for substitution

These factors can delay generic adoption even after legal barriers clear.

How does ATROPEN compare with competing atropine products on IP and commercial fundamentals?

Featured snippet: For atropine therapeutics, competition typically comes from other atropine sulfate presentations, alternative anticholinergics, and repackaged strengths, with substitution speed determined by label equivalence and procurement.

Commercial comparison framework for investment diligence

A comparable set should align on:

• Route: ophthalmic vs injectable
• Strength and dosing equivalence
• Indications and pediatric language alignment
• Supply capacity and lead time
• Distributor relationships

A market comparison cannot be populated without the relevant comparator list for ATROPEN.

What manufacturing and IP barriers could block generic or competitor supply for ATROPEN?

Featured snippet: For injectable and ophthalmic formats, CMC and sterility assurance can act as practical barriers even when composition patents are expired.

CMC risk factors that drive launch delays

Potential barriers include:

• Aseptic processing validation readiness
• Container closure system qualification
• OOS rate and sterility assurance testing capacity
• Stability program duration and expiry specification compliance

A product-specific assessment requires ATROPEN’s current manufacturing sites and any known regulatory actions.

Investment scenario: base case, bull case, and bear case financial drivers for ATROPEN

Featured snippet: For mature drugs like ATROPEN, the investment model usually prices cash-flow stability against generic price erosion and supply continuity risk.

Base case (most likely): mature market with limited price elasticity

Drivers:

• Stable demand in emergency and ophthalmic settings
• Continued formulary presence
• Periodic procurement-based volume swings
• Gradual margin compression from competition

Bear case: accelerated generic substitution and margin collapse

Drivers:

• Loss of any remaining listing protection for a specific strength/form
• Authorized generic or cheaper distributor channel adoption
• Supply interruptions that force higher-cost sourcing or contract losses

Bull case: protected pockets (strength/form/presentation) plus supply-driven premium

Drivers:

• Any remaining unexpired patents/exclusivities for a specific presentation
• Limited supplier capacity among qualified manufacturers
• Contract wins in critical care distribution

No quantitative revenue, EBITDA, or market share forecasts can be produced without the product’s pricing history, volumes, and competitive set.

Key patent-exclusivity dossier needed for a defensible investment thesis (what to verify)

Featured snippet: A credible investment thesis for ATROPEN requires a product-specific dossier tied to the Orange Book.

Dossier item	Investment relevance	What must be verified
Orange Book listing	Determines legal entry timing	NDA, dosage form, strength, patent list, exclusivity codes, expirations
Patent claim type	Determines enforceability and workarounds	composition vs method-of-use vs formulation vs manufacturing
Litigation status	Defines stay/settlement or injunction risk	active ANDA cases, Paragraph IV filings, consent decrees
Label and pediatric constraints	Drives substitution speed in hospitals	indication language, dosing, administration instructions
CMC capacity	Drives practical barriers	manufacturing sites, sterility assurance, stability, OOS history
Contracting and distribution	Drives realized pricing	GPO status, distributor allocation, tender cycle

Key Takeaways

• ATROPEN investment fundamentals are dominated by product-specific exclusivity and patent listing status, not by a new-drug style long runway.
• The decisive diligence step is an Orange Book-to-product match by strength and dosage form to confirm whether any unexpired patents or exclusivities remain.
• Generic entry risk is dosage-form specific and can be mitigated in practice by CMC/sterility barriers and hospital contracting cycles, even after legal barriers clear.
• Patent litigation exposure matters only if there are active US Paragraph IV cases tied to the specific Orange Book-listed patents for ATROPEN.

FAQs

1. How do I model generic entry risk for an older atropine brand like ATROPEN?
   Use product-specific Orange Book patent and exclusivity expirations, then apply 30-month stay and litigation/settlement effects, followed by procurement timing and substitution constraints by route and strength.

2. What is the biggest driver of margins for injectable vs ophthalmic atropine products?
   Injectable ophthalmics typically face higher CMC and sterility costs; margin durability depends on qualified supply capacity and contract pricing rather than only legal exclusivity.

3. Can a generic launch if only some strengths of ATROPEN are blocked?
   Yes, entry can occur for unblocked strengths/forms; market impact depends on formulary alignment and whether hospitals treat the product as substitutable across presentations.

4. Do method-of-use patents change generic risk for atropine indications?
   Yes, if the method-of-use covers a clinically specific dosing regimen tied to the label; risk depends on whether the generic’s label design avoids the patented regimen.

5. What litigation outcomes matter most for investor underwriting?
   For US: whether patents are upheld, whether settlements fix launch dates, and whether any injunction or consent judgment delays commercial supply beyond statutory exclusivity.

References

(No sources were cited because no ATROPEN-specific regulatory record, Orange Book identifiers, patent numbers, or litigation dockets were provided in the input.)